Transactions
1
Insider / BridgeBio Oncology Therapeutics, Inc.
BridgeBio Pharma LLC
Insider at BridgeBio Oncology Therapeutics, Inc.
- Ticker
- BBOT
- First filing on record
- October 16, 2025
- Latest trade on record
- October 10, 2025
- SEC filings
- EDGAR ↗
BridgeBio Pharma LLC, Insider at BridgeBio Oncology Therapeutics, Inc., has disclosed 1 transaction in BBOT since October 16, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed October 16, 2025, 6 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
6.0d
Trading in charts
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| J | Other acquisition or disposal | 1 | 784,720 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BBOT | Other J | October 10, 2025 | October 16, 2025 | 6d | 784,720 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 16, 2025 | Form 4 | 0001193125-25-241634 | 1 | published | EDGAR ↗ |
Other insiders at BridgeBio Oncology Therapeutics, Inc.
- Kumar Neil Chief Executive Officer 158 rows
- MCCORMICK FRANK Director 9 rows
- Beltran Pedro Chief Scientific Officer 6 rows
- Cobo Marc Principal Accounting Officer 6 rows
- Ben Yong Chief Med & Dev Officer 5 rows
- Chen Bihua Director 5 rows
- Bauer Jake Director 3 rows
- Elmelech Idan COO & Principal Financial Ofcr 3 rows
- Mehra Uneek Chief Financial Officer 3 rows
- Wallace Eli M. Chief Executive Officer 3 rows
Everyone on file, with contracts and lobbying under the company's name: BridgeBio Oncology Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | October 16, 2025 | October 16, 2025 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.